Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microarray analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

ABSTRACT: Microarray analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

PROVIDER: PRJNA950383 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

Project description:RNA-seq analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

| PRJNA950899 | ENA

Microarray analysis of mouse bone marrow hematopoietic progenitors

Project description:Microarray analysis of mouse bone marrow hematopoietic progenitors

| PRJNA950378 | ENA

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Project description:This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by stopping them from dividing or killing them. Giving cyclophosphamide after transplant may also stop the patient’s immune system from rejecting the donor’s bone marrow stem cells. The donated stem cells may replace the patient’s immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening

| 2008483 | ecrin-mdr-crc

Microarray analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

Project description:Microarray analysis of differentially expressed genes in wild-type and NFAT5-deficient hematopoietic stem cells (HSC) and multipotent progenitors (MPP)

2024-09-13 | GSE228575 | GEO

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Project description:This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.

| 2099113 | ecrin-mdr-crc

Microarray analysis of mouse bone marrow hematopoietic progenitors in steady state conditions

Project description:Microarray analysis of mouse bone marrow hematopoietic progenitors in steady state conditions

| PRJNA950382 | ENA

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Project description:RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body’s normal cells. Giving cyclosporine, methylprednisolone, and methotrexate after transplant may stop this from happening. PURPOSE: This clinical trial studies high-dose busulfan and high-dose cyclophosphamide followed by donor bone marrow transplant in treating patients with leukemia, myelodysplastic syndrome, multiple myeloma, or recurrent Hodgkin or Non-Hodgkin lymphoma.

| 2093228 | ecrin-mdr-crc

Microarray expression data from bone marrow monocytes and myeloid progenitors

Project description:Microarray expression data from bone marrow monocytes and myeloid progenitors

| PRJNA904028 | ENA

RNA-seq analysis of mouse bone marrow hematopoietic progenitors after bone marrow transplant

Project description:RNA-seq analysis of differentially expressed genes in wild-type, NFAT5-deficient, IFNAR1-deficient and double deficient (NFAT5 and IFNAR1) hematopoietic stem cells (HSC) and multipotent progenitors (MPP)

2024-09-11 | GSE228634 | GEO

microRNA expression in LKS hematopoietic progenitors vs. total bone marrow

Project description:Agilent chip was used to measure microRNA expression in the Lin- cKit+ Sca1+ bone marrow compartment and in total bone marrow. RNA was isolated by miRNeasy (Qiagen) from 1) Lin-cKit+Sca1+ cells, isolated from bone marrow using MACS column purification followed by fluorescent cell sorting, and 2) total Bone Marrow. Agilent microRNA microarray was run on these two samples.

2010-07-09 | E-GEOD-22844 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data